+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric lymphoma), By End Use, By Region And Segment Forecasts, 2025 - 2033- Product Image
Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric lymphoma), By End Use, By Region And Segment Forecasts, 2025 - 2033- Product Image
New

Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric lymphoma), By End Use, By Region And Segment Forecasts, 2025 - 2033

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Grand View Research
  • ID: 6111307
Description Jump to:

Gastric Cancer Diagnostics Market Summary

The global gastric cancer diagnostics market was estimated at USD 1.18 billion in 2024 and is projected to reach USD 2.22 billion by 2033, growing at a CAGR of 7.43% from 2025 to 2033. The market is growing, driven by the rising incidence of gastric cancer, growing emphasis on early detection and screening programs, and escalating demand for personalized medicines.

Gastric cancer ranks as the 5th most common cancer worldwide, and its rising incidence drives the demand for advanced diagnostic tools, highlighting the urgent need for early detection and improved patient outcomes. According to the National Cancer Institute (NIH), in 2025, it is projected that there will be approximately 30,300 new stomach cancer cases, with about 10,780 deaths expected from the disease

Some of the factors, such as Helicobacter pylori infection, smoking, high-salt diets, and aging, are contributing to a higher disease burden. The mortality rate for gastric cancer rises as people get older. In 2019 and 2023, the age-adjusted death rate for both men and women was 2.7 per 100,000 individuals annually. The chart below illustrates the percentage of new cases (%) by age group of gastric cancer for the period 2019-2022

Gastric cancer, being one of the leading causes of cancer-related deaths worldwide, has led to a rising demand for its early, accurate diagnostic tools. Healthcare systems are placing greater emphasis on screening programs and early detection, which drives the need for endoscopy, biopsy, imaging technologies, and molecular diagnostics, significantly expanding the market for both conventional and advanced diagnostic solutions.

Another factor for market growth is growing screening programs that the governments and healthcare organizations worldwide are implementing to detect gastric cancer in high-risk populations at earlier, more treatable stages. For instance in April, 2025, National Institutes of Health (NIH) has awarded a researcher USD 2.6 million over five years to lead a national team of researchers, clinicians, and computer scientists in evaluating the feasibility of gastric cancer screening in the U.S. Early detection significantly improves survival rates, prompting increased investments in diagnostic infrastructure. Countries like Japan and South Korea have established nationwide screening initiatives that include endoscopic examinations, which have proven effective in reducing mortality. As similar programs expand to other regions, the need for accurate and efficient diagnostic tools grows. This push toward preventive oncology and early-stage detection is a powerful driver of the gastric cancer diagnostics industry, especially as public health systems seek to reduce long-term treatment costs.

The shift toward personalized medicine is significantly influencing the gastric cancer diagnostics industry. Biomarker-based tests and genomic profiling allow clinicians to tailor treatments to individual patient profiles, improving therapeutic outcomes. This precision approach relies on advanced diagnostic tools such as next-generation sequencing (NGS), immunohistochemistry, and companion diagnostics. As targeted therapies become more prevalent, the need for molecular diagnostics to identify HER2, PD-L1, MSI, and other biomarkers in gastric cancer grows. Personalized medicine improves survival and enhances the cost-effectiveness of care, encouraging both healthcare providers and payers to adopt more advanced diagnostic platforms. For example, in metastatic biliary tract cancers, younger individuals tended to have a better prognosis than older patients, because their tumors were more likely to contain actionable genetic alterations that made them suitable candidates for personalized treatments.

Biomarkers can detect earlier molecular and genetic changes associated with cancer development, which is crucial for improving patient outcomes. Biomarkers, especially those found in blood or other body fluids, provide non-invasive or minimally invasive options, reducing patient discomfort compared to endoscopy or biopsy. They also allow for real-time monitoring of disease progression and treatment response, facilitating personalized medicine. Moreover, biomarkers can help differentiate between benign and malignant lesions with higher sensitivity and specificity, overcoming limitations of imaging such as low resolution or operator dependency. Hence, some emerging trends in biomarkers for gastric cancer diagnostics are listed below.

Global Gastric Cancer Diagnostics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, the analyst has segmented the global gastric cancer diagnostics market report based on product, disease type, end use, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Reagents & Consumables
  • Instruments

Disease Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Adenocarcinoma
  • Gastric lymphoma
  • Others

End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals
  • Diagnostic Laboratories
  • Diagnostic Imaging
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Disease Type
1.2.3. End use
1.2.4. Regional scope
1.2.5. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Disease type outlook
2.2.3. End use outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Gastric Cancer Diagnostics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Gastric Cancer Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
Chapter 4. Gastric Cancer Diagnostics Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Segment Dashboard
4.3. Gastric Cancer Diagnostics Market: Product Movement Analysis
4.4. Gastric Cancer Diagnostics Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.5. Gastric Cancer Diagnostics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Reagents & consumables
4.6.1. Reagents & consumables Market estimates and forecasts 2021 to 2033 (USD Million)
4.7. Instruments
4.7.1. Instruments Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Gastric Cancer Diagnostics Market: Disease Type Estimates & Trend Analysis
5.1. Disease Type Market Share, 2024 & 2033
5.2. Segment Dashboard
5.3. Global Gastric Cancer Diagnostics Market by Disease Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
5.5. Adenocarcinoma
5.5.1. Adenocarcinoma Market estimates and forecasts 2021 to 2033 (USD Million)
5.6. Gastric lymphoma
5.6.1. Gastric Lymphoma Market estimates and forecasts 2021 to 2033 (USD Million)
5.7. Others
5.7.1. Others Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Gastric Cancer Diagnostics Market: End Use Estimates & Trend Analysis
6.1. End Use Market Share, 2024 & 2033
6.2. Segment Dashboard
6.3. Global Gastric Cancer Diagnostics Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
6.5. Hospitals
6.5.1. Hospitals Market estimates and forecasts 2021 to 2033 (USD Million)
6.6. Diagnostic Laboratories
6.6.1. Diagnostic Laboratories Market estimates and forecasts 2021 to 2033 (USD Million)
6.7. Diagnostic Imaging
6.7.1. Diagnostic Imaging Market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Gastric Cancer Diagnostics Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts, Trend Analysis, 2021 to 2033:
7.5. North America
7.5.1. North America: SWOT Analysis
7.5.2. U.S.
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework/Reimbursement
7.5.2.3. Competitive scenario
7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
7.5.3. Canada
7.5.3.1. Key country dynamics
7.5.3.2. Regulatory framework/Reimbursement
7.5.3.3. Competitive scenario
7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
7.5.4. Mexico
7.5.4.1. Key country dynamics
7.5.4.2. Regulatory framework/Reimbursement
7.5.4.3. Competitive scenario
7.5.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
7.6. Europe
7.6.1. Europe: SWOT Analysis
7.6.2. UK
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework/Reimbursement
7.6.2.3. Competitive scenario
7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
7.6.3. Germany
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework/Reimbursement
7.6.3.3. Competitive scenario
7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
7.6.4. France
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework/Reimbursement
7.6.4.3. Competitive scenario
7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
7.6.5. Italy
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework/Reimbursement
7.6.5.3. Competitive scenario
7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
7.6.6. Spain
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework/Reimbursement
7.6.6.3. Competitive scenario
7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
7.6.7. Norway
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework/Reimbursement
7.6.7.3. Competitive scenario
7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
7.6.8. Sweden
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework/Reimbursement
7.6.8.3. Competitive scenario
7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
7.6.9. Denmark
7.6.9.1. Key country dynamics
7.6.9.2. Regulatory framework/Reimbursement
7.6.9.3. Competitive scenario
7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
7.7. Asia Pacific
7.7.1. Asia Pacific: SWOT Analysis
7.7.2. Japan
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework/Reimbursement
7.7.2.3. Competitive scenario
7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
7.7.3. China
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework/Reimbursement
7.7.3.3. Competitive scenario
7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
7.7.4. India
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework/Reimbursement
7.7.4.3. Competitive scenario
7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
7.7.5. Australia
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework/Reimbursement
7.7.5.3. Competitive scenario
7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
7.7.6. South Korea
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework/Reimbursement
7.7.6.3. Competitive scenario
7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
7.7.7. Thailand
7.7.7.1. Key country dynamics
7.7.7.2. Regulatory framework/Reimbursement
7.7.7.3. Competitive scenario
7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
7.8. Latin America
7.8.1. Latin America: SWOT Analysis
7.8.2. Brazil
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework/Reimbursement
7.8.2.3. Competitive scenario
7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework/Reimbursement
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
7.9. MEA
7.9.1. MEA: SWOT Analysis
7.9.2. South Africa
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework/Reimbursement
7.9.2.3. Competitive scenario
7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
7.9.3. Saudi Arabia
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework/Reimbursement
7.9.3.3. Competitive scenario
7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
7.9.4. UAE
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework/Reimbursement
7.9.4.3. Competitive scenario
7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
7.9.5. Kuwait
7.9.5.1. Key country dynamics
7.9.5.2. Regulatory framework
7.9.5.3. Competitive scenario
7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2024
8.3.4. MiRXES Pte Ltd.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Agilent Technologies Inc
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Endofotonics Pte Ltd
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Bio-Rad Laboratories, Inc
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Hipro Biotechnology Co., Ltd
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Exact Sciences Corporation
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. QIAGEN
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Fulgent Genetics.
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. F. Hoffmann-La Roche Ltd
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Abbott
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviations
Table 2 North America Gastric Cancer Diagnostics market, by region, 2021 - 2033 (USD Million)
Table 3 North America Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 4 North America Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 5 North America Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 6 U.S Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 7 U.S Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 8 U.S Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 9 Canada Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 10 Canada Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 11 Canada Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 12 Mexico Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 13 Mexico Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 14 Mexico Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 15 Europe Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 16 Europe Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 17 Europe Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 18 UK Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 19 UK Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 20 UK Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 21 Germany Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 22 Germany Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 23 Germany Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 24 France Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 25 France Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 26 France Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 27 Italy Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 28 Italy Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 29 Italy Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 30 Spain Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 31 Spain Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 32 Spain Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 33 Denmark Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 34 Denmark Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 35 Denmark Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 36 Sweden Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 37 Sweden Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 38 Sweden Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 39 Norway Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 40 Norway Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 41 Norway Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 42 Asia Pacific Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 43 Asia Pacific Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 44 Asia Pacific Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 45 Japan Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 46 Japan Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 47 Japan Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 48 China Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 49 China Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 50 China Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 51 India Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 52 India Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 53 India Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 54 Australia Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 55 Australia Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 56 Australia Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 57 South Korea Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 58 South Korea Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 59 South Korea Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 60 Thailand Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 61 Thailand Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 62 Thailand Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 63 Latin America Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 64 Latin America Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 65 Latin America Gastric Cancer Diagnostics market, by end use 2021 - 2033 (USD Million)
Table 66 Brazil Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 67 Brazil Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 68 Brazil Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 69 Argentina Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 70 Argentina Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 71 Argentina Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 72 MEA Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 73 MEA Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 74 MEA Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 75 South Africa Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 76 South Africa Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 77 South Africa Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 78 Saudi Arabia Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 79 Saudi Arabia Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 80 Saudi Arabia Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 81 UAE Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 82 UAE Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 83 UAE Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
Table 84 Kuwait Gastric Cancer Diagnostics market, by product, 2021 - 2033 (USD Million)
Table 85 Kuwait Gastric Cancer Diagnostics market, by disease type, 2021 - 2033 (USD Million)
Table 86 Kuwait Gastric Cancer Diagnostics market, by end use, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Gastric Cancer Diagnostics market: market outlook
Fig. 14 Gastric Cancer Diagnostics Competitive Insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Gastric Cancer Diagnostics Market Driver Impact
Fig. 20 Gastric Cancer Diagnostics Market Restraint Impact
Fig. 21 Gastric Cancer Diagnostics Market Strategic Initiatives Analysis
Fig. 22 Gastric Cancer Diagnostics market: Product movement analysis
Fig. 23 Gastric Cancer Diagnostics market: Product outlook and key takeaways
Fig. 24 Reagents & consumables market estimates and forecasts, 2021 - 2033
Fig. 25 Instruments market estimates and forecasts,2021 - 2033
Fig. 26 Gastric Cancer Diagnostics Market: Disease Type Movement Analysis
Fig. 27 Gastric Cancer Diagnostics market: Disease type outlook and key takeaways
Fig. 28 Adenocarcinoma market estimates and forecasts, 2021 - 2033
Fig. 29 Gastric lymphoma market estimates and forecasts, 2021 - 2033
Fig. 30 Other market estimates and forecasts, 2021 - 2033
Fig. 31 Gastric Cancer Diagnostics Market: End use movement analysis
Fig. 32 Gastric Cancer Diagnostics market: End use outlook and key takeaways
Fig. 33 Hospitals market estimates and forecasts, 2021 - 2033
Fig. 34 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
Fig. 35 Diagnostic Imaging market estimates and forecasts, 2021 - 2033
Fig. 36 Global Gastric Cancer Diagnostics market: Regional movement analysis
Fig. 37 Global Gastric Cancer Diagnostics market: Regional outlook and key takeaways
Fig. 38 Global Gastric Cancer Diagnostics market share and leading players
Fig. 39 North America market share and leading players
Fig. 40 Europe market share and leading players
Fig. 41 Asia Pacific market share and leading players
Fig. 42 Latin America market share and leading players
Fig. 43 Middle East & Africa market share and leading players
Fig. 44 North America, by country
Fig. 45 North America
Fig. 46 North America market estimates and forecasts, 2021 - 2033
Fig. 47 U.S.
Fig. 48 U.S. market estimates and forecasts, 2021 - 2033
Fig. 49 Canada
Fig. 50 Canada market estimates and forecasts, 2021 - 2033
Fig. 51 Mexico
Fig. 52 Mexico market estimates and forecasts, 2021 - 2033
Fig. 53 Europe
Fig. 54 Europe market estimates and forecasts, 2021 - 2033
Fig. 55 UK
Fig. 56 UK market estimates and forecasts, 2021 - 2033
Fig. 57 Germany
Fig. 58 Germany market estimates and forecasts, 2021 - 2033
Fig. 59 France
Fig. 60 France market estimates and forecasts, 2021 - 2033
Fig. 61 Italy
Fig. 62 Italy market estimates and forecasts, 2021 - 2033
Fig. 63 Spain
Fig. 64 Spain market estimates and forecasts, 2021 - 2033
Fig. 65 Denmark
Fig. 66 Denmark market estimates and forecasts, 2021 - 2033
Fig. 67 Sweden
Fig. 68 Sweden market estimates and forecasts, 2021 - 2033
Fig. 69 Norway
Fig. 70 Norway market estimates and forecasts, 2021 - 2033
Fig. 71 Asia Pacific
Fig. 72 Asia Pacific market estimates and forecasts, 2021 - 2033
Fig. 73 China
Fig. 74 China market estimates and forecasts, 2021 - 2033
Fig. 75 Japan
Fig. 76 Japan market estimates and forecasts, 2021 - 2033
Fig. 77 India
Fig. 78 India market estimates and forecasts, 2021 - 2033
Fig. 79 Thailand
Fig. 80 Thailand market estimates and forecasts, 2021 - 2033
Fig. 81 South Korea
Fig. 82 South Korea market estimates and forecasts, 2021 - 2033
Fig. 83 Australia
Fig. 84 Australia market estimates and forecasts, 2021 - 2033
Fig. 85 Latin America
Fig. 86 Latin America market estimates and forecasts, 2021 - 2033
Fig. 87 Brazil
Fig. 88 Brazil market estimates and forecasts, 2021 - 2033
Fig. 89 Argentina
Fig. 90 Argentina market estimates and forecasts, 2021 - 2033
Fig. 91 Middle East and Africa
Fig. 92 Middle East and Africa market estimates and forecasts, 2021 - 2033
Fig. 93 South Africa
Fig. 94 South Africa market estimates and forecasts, 2021 - 2033
Fig. 95 Saudi Arabia
Fig. 96 Saudi Arabia market estimates and forecasts, 2021 - 2033
Fig. 97 UAE
Fig. 98 UAE market estimates and forecasts, 2021 - 2033
Fig. 99 Kuwait
Fig. 100 Kuwait market estimates and forecasts, 2021 - 2033
Fig. 101 Market share of key market players- Gastric Cancer Diagnostics market

Companies Mentioned

  • MiRXES Pte Ltd
  • Agilent Technologies Inc
  • Endofotonics Pte Ltd
  • Bio-Rad Laboratories, Inc
  • Hipro Biotechnology Co., Ltd
  • F. Hoffmann-La Roche Ltd.
  • Exact Sciences Corporation
  • QIAGEN
  • Fulgent Genetics
  • Abbott

Table Information

Report AttributeDetails
No. of Pages150
PublishedJune 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 1.18 Billion
Forecasted Market Value ( USD ) by 2033 $ 2.22 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

U.S. Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric Lymphoma), By End-use (Diagnostic Laboratories), And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Gastric Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Reagents & Consumables, Instruments), By Disease Type (Adenocarcinoma, Gastric Lymphoma), By End-use (Diagnostic Laboratories), And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • United States
From
Tissue Diagnostics Market Report by Product Type, Technology, Disease, End-User, and Region 2025-2033 - Product Image

Tissue Diagnostics Market Report by Product Type, Technology, Disease, End-User, and Region 2025-2033

  • Report
  • 139 Pages
  • Global
From
U.S. Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (Flow Cytometry, PCR, NGS), By Cancer Type (Hematological Malignancy, Solid Tumors), By End Use, And Segment Forecasts, 2025 - 2033 - Product Image

U.S. Minimal Residual Disease Testing Market Size, Share & Trends Analysis Report By Technology (Flow Cytometry, PCR, NGS), By Cancer Type (Hematological Malignancy, Solid Tumors), By End Use, And Segment Forecasts, 2025 - 2033

  • Report
  • 100 Pages
  • United States
From
U.S. Tissue Diagnostics Market Size, Share & Trends Analysis Report By Technology & Product, By Application, And Segment Forecasts, 2025 - 2030 - Product Image

U.S. Tissue Diagnostics Market Size, Share & Trends Analysis Report By Technology & Product, By Application, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • United States
From
Gastric Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Gastric Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.